Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Issues $800M of Senior Notes

NEW YORK (GenomeWeb) – Thermo Fisher Scientific issued $800 million in aggregate principal amount of 3.3 percent senior notes due in 2022, the company said in a document filed with the US Securities and Exchange Commission on Friday after the close of the market. 

The company announced its plans to offer the dollar-denominated notes and then priced them earlier this month. The company will use net proceeds principally to pay back debt, including the $400 million aggregate principal amount of its 3.25 percent senior notes due 2014 that mature on Nov. 20, it said. The company has also filed a registration document with the SEC for a euro-denominated offering of its senior notes due in 2025. 

The joint book-running managers for the offering are Merrill Lynch, Pierce, Fenner & Smith; Mitsubishi UFJ Securities; Citigroup Global Markets; and Credit Suisse Securities.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.